Radiation oncology firm Accuray posted an 11% increase in its 2016 second-quarter revenue (end-December 31), compared with the same period in 2015.
Total revenue for the quarter was $109 million, compared with $98.2 million in 2015. Net loss for the quarter was $6 million, compared with a net loss of $10 million for the same period last year.
For the six-month period, Accuray's total revenue was $198.5 million, an increase of 10% over 2015's $180.5 million. Net loss was $19.1 million, compared with $31.6 million the previous year, Accuray said.
The company reaffirmed its previous financial guidance for fiscal 2016, anticipating total revenues between $395 million and $410 million.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
